الفهرس 
HEPATITIS C VIRUS INFECTION AND PROGRESSION OF LIVER DISEASE
Cytokine responseOnly 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
HCV infection is a major cause of liver cirrhosis, (HCC)
and end-stage liver disease. The development of an interferonfree,
all-oral treatment regimen represents an important
advance. We evaluated daclatasvir (an HCV NS5A replication
complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV
NS5B polymerase inhibitor) with or without Ribavirin in
chronic HCV patients.
Results
Sustained virological response (12 weeks ) after end of
the treatment in more than 90% of patients , Liver function
parameters including albumin, bilirubin, and prothrombin time
and liver enzymes Ast , Alt improved in the majority of
patients during and after the end of therapy ,but there is
significant increase in urea level , serum creatinin and HbA1C.
There is significant decrease in LDL and mild increase in
TG level.
Conclusion
Once-daily oral daclatasvir plus sofosbuvir with or
without Ribavirin was associated with high rates of sustained
virologic response among patients infected with HCV ,
including chronic cirrhotic patients and relapsers , successful
treatment associated with Improvement of liver function parameters in the majority of patients , Increase in urea level,
serum creatinin and HbA1C.
There is significant decrease in LDL and mild increase in
TG level.
Recommendations
To avoid side effects of DAAs on patients, they have to
restrict diet and continue medical treatment of diabetes
with follow up RBS.
During treatment, patient must follow up renal function
to avoid the side effects of drug.
Good monitoring for hyperlipidemia to avoid ischemic
heart disease..